Psychedelics Psilera raises US$8.8M to fight dementia with non-psychoactive psilocybin drug The biotech is preparing for in-human trials with 'PSIL-006' next year Rowan Dunne4 days ago
Psychedelics Deutsche Bank initiates bullish coverage of psychedelics company AtaiBeckley The financial institution has given the drug developer a Buy rating a US$12 share target Rowan DunneMarch 31, 2026